Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with a TP53 mutation presented in an oral presentation at the 50th EBMT annual meeting
Stockholm, April 18, 2024 – Immedica’s partner Actinium Pharmaceuticals, Inc. presented results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation in an oral presentation at the 50th Annual meeting of the European Society for Blood and Marrow Trasnplantation (EBMT) held April 14 – 17, 2024, in Glasgow, Scotland. Iomab-B is a targeted radiotherapy agent comprised of an anti-CD45 monoclonal antibody conjugated to Iodine-131 radioisotope payload. The Phase 3 SIERRA trial enrolled 153 patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and compared outcomes of patients receiving Iomab-B and allogeneic haematopoietic stem cell transplantation (alloHSCT) to those of patients receiving physician's choice of care in the control arm. In total, 24% (37/153) of patients in the SIERRA trial had a TP53 mutation, which is usually associated with poor outcomes, 27 of these patients received Iomab-B. Iomab-B led alloHSCT significantly improved survival outcomes compared to conventional care in this very high-risk patient population with TP53 mutations.
Dr. Hannah Choe, Assistant Professor of Medicine at Ohio State University and SIERRA trial investigator presented the SIERRA results. Details of the oral presentation are as follows:
Title: I-131-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Demonstrates Survival Benefit and Overcomes High-Risk TP53 Mutations in Patients with R/R AML
Date and Time: Wednesday, April 17, 2024, 12:39 PM GMT
Session: OS17-02
Location: Scottish Event Campus (SEC Centre)
About the EBMT Annual Meeting
The Annual Meeting of the EBMT is attended by more than 5,500 participants, including physicians, nurses, data managers, statisticians, quality managers, cell therapists, pediatricians, pharmacists, psychologists, psychiatrists and psychoanalysts, transplant coordinators, lab scientists, trainees, patients. This important congress ensures and encourages dialogues and information exchange, education and scientific productivity.
The full annual meeting program is available online at:
https://ebmt2024.abstractserver.com/program/#/program/2/horizontal.
About Actinium Pharmaceuticals, Inc.
Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidate Iomab-B (pre-BLA & MAA (EU)) is an induction and conditioning agent prior to bone marrow transplant. Actinium plans to advance Iomab-B for other blood cancers to potentially improve cell and gene therapy outcomes. Actinium holds more than 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.
For more information, please visit: https://www.actiniumpharma.com/
About Immedica
Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.
Immedica was founded in 2018 by the investment company Impilo and Buy-in-Management. Today Immedica employs more than 100 people across Europe and the Middle East.
For more information visit www.immedica.com
Immedica contact:
Linda Holmström
Head of Communication
linda.holmstrom@immedica.com
+ 46 708 73 40 95
Immedica Pharma AB
Solnavägen 3H
SE-113 63 Stockholm